View Older Stories View More Recent Stories

Oct 1, 2021 08:00AM I-Mab Announces Upcoming Participation at October Conferences
Sep 30, 2021 08:02AM I-Mab Biopharma (IMAB) Reports Multiple Positive Clinical Updates of Differentiated CD47 Antibody Lemzoparlimab
Sep 30, 2021 08:00AM I-Mab Reports Multiple Positive Clinical Updates of Differentiated CD47 Antibody Lemzoparlimab
Sep 28, 2021 08:02AM I-Mab Biopharma (IMAB) Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors
Sep 28, 2021 08:00AM I-Mab Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors
Sep 13, 2021 08:00AM I-Mab Added to FTSE ESG Index Series
Sep 2, 2021 08:00AM I-Mab Added to FTSE Russell Global Equity Index Series
Aug 31, 2021 06:00AM I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2021
Aug 30, 2021 08:00AM I-Mab Announces Upcoming Participation at September Conferences
Aug 19, 2021 07:00AM I-Mab Announces Establishment of Environmental, Social and Governance Committee
Aug 17, 2021 08:00AM I-Mab to Provide Business and Corporate Updates and Report Financial Results for the Six Months Ended June 30, 2021 on August 31, 2021
Aug 11, 2021 08:02AM I-Mab Biopharma (IMAB) Reports Interim Analysis from Phase 2/3 Study of its GM-CSF Antibody Plonmarlimab (TJM2) to Treat Patients with Severe COVID-19
Aug 11, 2021 08:00AM I-Mab Reports Positive Interim Analysis from Phase 2/3 Study of its GM-CSF Antibody Plonmarlimab (TJM2) to Treat Patients with Severe COVID-19
Jul 30, 2021 08:06AM I-Mab Biopharma (IMAB) Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's Disease
Jul 30, 2021 08:00AM I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's Disease
Jul 29, 2021 08:13AM I-Mab Biopharma (IMAB) Announces Authorization of a Renewed Stock Repurchase Program by the Company up to US$40 Million
Jul 29, 2021 08:00AM I-Mab Announces Authorization of a Renewed Stock Repurchase Program by the Company up to US$40 Million
Jul 28, 2021 07:15AM I-Mab Biopharma (IMAB) Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China
Jul 28, 2021 07:15AM I-Mab Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China
Jul 27, 2021 08:40AM I-Mab Biopharma (IMAB) Announces Preliminary Proposal for Potential Dual Listing on the STAR Market of the Shanghai Stock Exchange
Jul 27, 2021 08:35AM I-Mab Announces Preliminary Proposal for Potential Dual Listing on the STAR Market of the Shanghai Stock Exchange
Jul 9, 2021 08:05AM I-Mab Biopharma (IMAB) signs two new collaborations with emerging biotech companies in China
Jul 9, 2021 08:00AM I-Mab Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through Cutting-Edge mRNA and AI Technology Platforms
Jul 1, 2021 08:06AM I-Mab Biopharma (IMAB) Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio
Jul 1, 2021 08:00AM I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio
Jun 30, 2021 08:00AM I-Mab Honored with Top Rankings by Institutional Investor
Jun 25, 2021 08:01AM I-Mab Biopharma (IMAB) Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus Erythematosus
Jun 25, 2021 08:00AM I-Mab Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus Erythematosus
Jun 21, 2021 08:00AM I-Mab Appoints International Gastrointestinal Oncology Expert Dr. Andrew Zhu to its Scientific Advisory Board
Jun 2, 2021 08:00AM I-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differentiated CD73 Antibody Uliledlimab
Jun 1, 2021 08:00AM I-Mab Appoints Ruyi He and Rong Shao to Board of Directors
May 27, 2021 08:00AM I-Mab Announces Upcoming Participation at June Conferences
May 19, 2021 06:00PM I-Mab Presents Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021
May 18, 2021 08:01AM I-Mab Biopharma (IMAB) Reports First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Azacitidine
May 18, 2021 08:00AM I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome
May 14, 2021 07:00AM ProMIS Neurosciences Announces First Quarter 2021 Results
May 14, 2021 07:00AM ProMIS Neurosciences Announces First Quarter 2021 Results
May 13, 2021 08:00AM I-Mab Added to MSCI China Index
Apr 29, 2021 08:00AM I-Mab Announces Upcoming Participation at May Conferences
Apr 28, 2021 08:00AM I-Mab Filed 2020 Annual Report on Form 20-F
Apr 26, 2021 07:01AM I-Mab Biopharma (IMAB) Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis
Apr 26, 2021 07:00AM I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis
Apr 14, 2021 08:30AM I-Mab Announces Selected Poster Presentation of CD73 Antibody Uliledlimab at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
Apr 14, 2021 08:30AM I-Mab Announces Selected Poster Presentation of CD73 Antibody Uliledlimab at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
Apr 6, 2021 08:00AM I-Mab and ABL Bio Announce First Patient Dosed in Phase 1 Trial of Bispecific Antibody TJ-L14B/ABL503 in Patients with Advanced or Metastatic Solid Tumors
Apr 6, 2021 08:00AM I-Mab and ABL Bio Announce First Patient Dosed in Phase 1 Trial of Bispecific Antibody TJ-L14B/ABL503 in Patients with Advanced or Metastatic Solid Tumors
Mar 31, 2021 08:00AM I-Mab Announces Upcoming Participation at April Conferences
Mar 31, 2021 08:00AM I-Mab Announces Upcoming Participation at April Conferences
Mar 30, 2021 08:04AM I-Mab Biopharma (IMAB) and ABL Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors
Mar 30, 2021 08:00AM I-Mab and ABL Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors
View More Recent Stories View Older Stories